Logo
TMO logo
Thermo Fisher Scientific Inc.
TMO
496.11 (-0.87%) 4.31
Health Care
Life Sciences Tools and Services
Thermo Fisher Scientific Inc. provides life sciences solutions analytical instruments specialty diagnostics and laboratory products and biopharma services in the North America Europe Asia-Pacific and internationally. It operates through four segments: Life Sciences Solutions Analytical Instruments Specialty Diagnostics and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents instruments and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments consumables software and services for pharmaceutical biotechnology academic government environmental and other research and industrial markets as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits calibrators controls protein detection assays and instruments; immunodiagnostic offerings comprising developing manufacturing and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy asthma and autoimmune diseases; microbiology offerings such as dehydrated and prepared culture media collection and transport systems instrumentation and consumables to detect pathogens in blood diagnostic and rapid direct specimen tests quality-control products and associated products; transplant diagnostics products including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products research and safety market channel and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham Massachusetts.

Quality Checklist 6/8

5Y Shares Out Change < 0%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
ROIC > 10%
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $184.30(B)
EV: $224.53(B)
Total Equity: $53.54(B)
Earnings date: Apr-23-2026
P/E: 27.90
Forward P/E: 20.22
P/FCF: 29.65
P/S: 4.20
P/B: 3.49
EPS: $17.8
EPS (fwd): $24.5
FCF/share: $16.7
Revenue/share: $118.2
Book value/share: $142.0
ROIC: 7.7%
ROA: 6.5%
ROE: 13.1%
Debt/Equity: 0.77
Current Ratio: 1.90
Gross margin: 41.1%
Operating margin: 18.4%
Net margin: 15.0%
Dividend/share: $1.7
Div. yield: 0.35%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$44.56(B)
Gross profit$18.30(B)
EBITDA$11.14(B)
Net income$6.70(B)
Gross margin41.1%
Operating margin18.4%
Net margin15.0%
Shares outstanding371.48(M)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$110.34(B)
Current assets$28.71(B)
Total liabilities$56.81(B)
Current liabilities$15.19(B)
Cash & Short-term inv.$10.11(B)
Long-term debt$36.15(B)
Total intangibles$65.20(B)
PP&E$12.01(B)

Cash flow (TTM)

CFOCFICFF
FCF$6.29(B)
CapEx$-1.52(B)
Dividends paid$-636.00(M)
Stock issued$0
Stock repurchased$-3.00(B)
Stock-based comp.$310.00(M)
Debt issued$8.85(B)
Debt repaid$-3.51(B)

Per share data (TTM)

Price: $496
Revenue: $118 (4.2x | 23.8%) Gross profit: $49.3 (10.1x | 9.9%) Earnings: $17.8 (27.9x | 3.6%)
FCF: $16.7 (29.7x | 3.4%) Stock-based Comp.: $0.83 (594.5x | 0.2%) CapEx.: $4.11 (120.9x | 0.8%) Dividend: $1.72 (288.4x | 0.3%)
Total Assets: $297 (1.7x | 59.9%) Total Liabilities: $153 (3.2x | 30.8%) Book Value: $142 (3.5x | 28.6%) Cash & ST inv.: $27.2 (18.2x | 5.5%) Debt: $97.3 (5.1x | 19.6%)
Earnings FY+1: $24.5 (20.2x | 4.9%) Earnings FY+2: $26.9 (18.4x | 5.4%) Earnings FY+3: $29.7 (16.7x | 6.0%) Earnings FY+4: $33.1 (15.0x | 6.7%) Earnings FY+5: $37.8 (13.1x | 7.6%)
FCF FY+1: $19.2 (25.8x | 3.9%) FCF FY+2: $24.1 (20.5x | 4.9%)

Summary

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact